Citadel Advisors
EWTX icon

Citadel Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Citadel Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.5M Buy
429,032
+305,935
+249% +$8.82M ﹤0.01% 2823
2025
Q4 		$3.05M Buy
123,097
+100,780
+452% +$2.02M ﹤0.01% 5117
2025
Q3 		$362K Sell
22,317
-302,932
-93% -$4.3M ﹤0.01% 9914
2025
Q2 		$4.26M Buy
325,249
+227,971
+234% +$3.29M ﹤0.01% 4395
2025
Q1 		$2.14M Sell
97,278
-372,173
-79% -$9.76M ﹤0.01% 5404
2024
Q4 		$12.5M Sell
469,451
-68,798
-13% -$2.19M ﹤0.01% 2691
2024
Q3 		$14.4M Sell
538,249
-1,810,925
-77% -$36M ﹤0.01% 2428
2024
Q2 		$42.3M Sell
2,349,174
-370,117
-14% -$6.46M 0.01% 1285
2024
Q1 		$49.6M Buy
2,719,291
+133,361
+5% +$2.12M 0.01% 1218
2023
Q4 		$28.3M Sell
2,585,930
-181,506
-7% -$1.27M 0.01% 1680
2023
Q3 		$15.9M Buy
2,767,436
+92,446
+3% +$628K ﹤0.01% 2128
2023
Q2 		$20.7M Sell
2,674,990
-93,448
-3% -$788K ﹤0.01% 1844
2023
Q1 		$18.5M Sell
2,768,438
-78,081
-3% -$724K ﹤0.01% 2003
2022
Q4 		$25.4M Buy
2,846,519
+84,795
+3% +$795K 0.01% 1715
2022
Q3 		$27.2M Buy
2,761,724
+223,706
+9% +$2.26M 0.01% 1579
2022
Q2 		$20.2M Sell
2,538,018
-101,782
-4% -$769K 0.01% 1845
2022
Q1 		$25.6M Buy
2,639,800
+181,359
+7% +$2.33M 0.01% 1714
2021
Q4 		$37.6M Buy
2,458,441
+33,257
+1% +$598K 0.01% 1411
2021
Q3 		$40.3M Sell
2,425,184
-34,967
-1% -$632K 0.01% 1296
2021
Q2 		$51.2M Buy
2,460,151
+78,003
+3% +$2.13M 0.01% 1105
2021
Q1 		$77.4M Buy
+2,382,148
New +$77.2M 0.02% 733

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citadel Advisors's EWTX Position: Q1 2026 in Review

Citadel Advisors increased its Edgewise Therapeutics (EWTX) stake by 249% in Q1 2026, buying an estimated $8.82M and bringing the position to 429,032 shares worth $13.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2823.

Citadel Advisors first reported a position in EWTX in Q1 2021 and has held it in 21 quarters since. The position peaked at $77.4M in Q1 2021. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Citadel Advisors held 429,032 shares of Edgewise Therapeutics worth $13.5M as of Q1 2026.
  • Citadel Advisors bought 305,935 Edgewise Therapeutics shares in Q1 2026, an estimated $8.82M.
  • Edgewise Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2823 holding.
  • Citadel Advisors first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Citadel Advisors's Edgewise Therapeutics position peaked at $77.4M in Q1 2021.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.